These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 28164586

  • 1. Plasma Levels and Diagnostic Utility of M-CSF, MMP-2 and its Inhibitor TIMP-2 in the Diagnostics of Breast Cancer Patients.
    Ławicki S, Zajkowska M, Głażewska EK, Będkowska GE, Szmitkowski M.
    Clin Lab; 2016 Sep 01; 62(9):1661-1669. PubMed ID: 28164586
    [Abstract] [Full Text] [Related]

  • 2. Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer.
    Ławicki S, Głażewska EK, Sobolewska M, Będkowska GE, Szmitkowski M.
    Ann Lab Med; 2016 May 01; 36(3):223-9. PubMed ID: 26915610
    [Abstract] [Full Text] [Related]

  • 3. Plasma levels and diagnostic utility of VEGF, MMP-2 and TIMP-2 in the diagnostics of breast cancer patients.
    Ławicki S, Zajkowska M, Głażewska EK, Będkowska GE, Szmitkowski M.
    Biomarkers; 2017 Mar 01; 22(2):157-164. PubMed ID: 27775427
    [Abstract] [Full Text] [Related]

  • 4. Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis.
    Lubowicka E, Zbucka-Kretowska M, Sidorkiewicz I, Zajkowska M, Gacuta E, Puchnarewicz A, Chrostek L, Szmitkowski M, Ławicki S.
    Pathol Oncol Res; 2020 Apr 01; 26(2):791-800. PubMed ID: 30820752
    [Abstract] [Full Text] [Related]

  • 5. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
    Ławicki S, Szmitkowski M, Wojtukiewicz M.
    Clin Chim Acta; 2006 Sep 01; 371(1-2):112-6. PubMed ID: 16631152
    [Abstract] [Full Text] [Related]

  • 6. Hematopoietic cytokines as tumor markers in breast malignancies. A multivariate analysis with ROC curve in breast cancer patients.
    Ławicki S, Będkowska GE, Wojtukiewicz M, Szmitkowski M.
    Adv Med Sci; 2013 Sep 01; 58(2):207-15. PubMed ID: 23846151
    [Abstract] [Full Text] [Related]

  • 7. VEGF, M-CSF and CA 15-3 as a new tumor marker panel in breast malignancies: a multivariate analysis with ROC curve.
    Ławicki S, Będkowska GE, Szmitkowski M.
    Growth Factors; 2013 Jun 01; 31(3):98-105. PubMed ID: 23688065
    [Abstract] [Full Text] [Related]

  • 8. [The plasma levels and diagnostic utility of selected hematopoietic growth factors (HGFs) in breast cancer patients].
    Ławicki S, Czygier M, Wojtukiewicz M, Szmitkowski M.
    Przegl Lek; 2010 Jun 01; 67(12):1314-8. PubMed ID: 21591359
    [Abstract] [Full Text] [Related]

  • 9. Comparative evaluation of plasma levels and diagnostic values of macrophage-colony stimulating factor in patients with breast cancer and benign tumors.
    Ławicki S, Czygier M, Bedkowska E, Wojtukiewicz M, Szmitkowski M.
    Pol Arch Med Wewn; 2008 Sep 01; 118(9):464-9. PubMed ID: 18846980
    [Abstract] [Full Text] [Related]

  • 10. Diagnostic Power of Vascular Endothelial Growth Factor and Macrophage Colony-Stimulating Factor in Breast Cancer Patients Based on ROC Analysis.
    Zajkowska M, Głażewska EK, Będkowska GE, Chorąży P, Szmitkowski M, Ławicki S.
    Mediators Inflamm; 2016 Sep 01; 2016():5962946. PubMed ID: 27445439
    [Abstract] [Full Text] [Related]

  • 11. [The plasma levels and diagnostic utility of granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage - colony stimulating factor (GM-CSF) in patients with I and II stage of breast cancer].
    Ławicki S, Czygier M, Wojtukiewicz M, Szmitkowski M.
    Przegl Lek; 2009 Sep 01; 66(7):365-9. PubMed ID: 20043577
    [Abstract] [Full Text] [Related]

  • 12. Plasma levels of VEGF-A, VEGF B, and VEGFR-1 and applicability of these parameters as tumor markers in diagnosis of breast cancer.
    Zajkowska M, Lubowicka E, Malinowski P, Szmitkowski M, Ławicki S.
    Acta Biochim Pol; 2018 Dec 13; 65(4):621-628. PubMed ID: 30543720
    [Abstract] [Full Text] [Related]

  • 13. M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients.
    Będkowska GE, Ławicki S, Gacuta E, Pawłowski P, Szmitkowski M.
    J Ovarian Res; 2015 May 03; 8():27. PubMed ID: 25935153
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Plasma levels and diagnostic utility of macrophage-colony stimulating factor, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 as tumor markers in cervical cancer patients.
    Zajkowska M, Zbucka-Krętowska M, Sidorkiewicz I, Lubowicka E, Gacuta E, Szmitkowski M, Chrostek L, Ławicki S.
    Tumour Biol; 2018 Jul 03; 40(7):1010428318790363. PubMed ID: 30052166
    [Abstract] [Full Text] [Related]

  • 17. Matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in the diagnosis of colorectal adenoma and cancer patients.
    Groblewska M, Mroczko B, Gryko M, Kędra B, Szmitkowski M.
    Folia Histochem Cytobiol; 2010 Dec 03; 48(4):564-71. PubMed ID: 21478099
    [Abstract] [Full Text] [Related]

  • 18. [The plasma levels of granulocyte-colony stimulating factor (G-CSF) and macrophage-colony stimulating factor (M-CSF) in breast cancer patients].
    Lawicki S, Czygier M, Omyła J, Szmitkowski M.
    Pol Arch Med Wewn; 2006 Aug 03; 116(2):749-55. PubMed ID: 17424919
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Diagnostic power of VEGF, MMP-9 and TIMP-1 in patients with breast cancer. A multivariate statistical analysis with ROC curve.
    Zajkowska M, Gacuta E, Kozłowska S, Lubowicka E, Głażewska EK, Chrostek L, Szmitkowski M, Pawłowski P, Zbucka-Krętowska M, Ławicki S.
    Adv Med Sci; 2019 Mar 03; 64(1):1-8. PubMed ID: 30227310
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.